Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Derek Doherty

Associate Professor, Head of Immunology (Immunology)
TRINITY CENTRE, S J H


A graduate of Trinity College Dublin, I completed a PhD at King's College London and postdoctoral research in the University of Washington, Seattle and University College Dublin before holding lecturing positions at NUI Maynooth and subsequently Trinity College Dublin.
  ADIPOSE-TISSUE   AUTOIMMUNE DISEASES   B-CELLS   CANCER   CELL-MEDIATED IMMUNE RESPONSES   DENDRITIC CELLS   GAMMA DELTA TCR   HEPATITIS B   HEPATITIS-C   HEPATOCELLULAR-CARCINOMA   HIV   HUMAN LIVER   IMMUNE SYSTEM   IMMUNODEFICIENCY   INFECTIOUS DISEASES   INNATE IMMUNITY   LEUKOCYTE   LIPIDS   LYMPHOCYTES   NATURAL-KILLER-CELLS
 CD1d binding peptide motifs for the stimulation of NKT cells.
 The role and treatment potential of innate lymphocytes in neonatal brain injury
 Metabolic profiles of innate lymphocytes from patients with sepsis
 The role and treatment potential of natural killer T cells in patients with upper gastrointestinal cancer
 Delivery of Gene Editing Tools to Primary T cells using Profector Technology

Page 1 of 7
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
Details Date From Date To
Secretary, Irish Society for Immunology 2000 2004
Committee member, Irish Society for Immunology 2000 2018
Doherty, D.G., Antigen-specific immune tolerance in the liver, Nature Biomedical Engineering, 2019, Notes: [cited By 0], Journal Article, PUBLISHED  DOI
Dockry É, O'Leary S, Gleeson LE, Lyons J, Keane J, Gray SG, Doherty DG, Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells, OncoImmunology, 2018, pe1428156-, Journal Article, PUBLISHED  URL
Petrasca A, Melo AM, Breen EP, Doherty DG, Human Vδ3+ γδ T cells induce maturation and IgM secretion by B cells, Immunology Letters, 196, 2018, 126-134 , Journal Article, PUBLISHED  DOI  URL
Galvin KC, Conroy MJ, Doyle SL, Dunne MR, Fahey R, Foley E, O'Sullivan KE, Doherty DG, Geoghegan JG, Ravi N, O'Farrelly C, Reynolds JV, Lysaght J, Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma, Cancer Letters, 418, 2018, 230 - 238, Journal Article, PUBLISHED  URL
Fazekas B, Moreno-Olivera A, Kelly Y, O'Hara P, Murray S, Kennedy A, Conlon N, Scott J, Melo AM, Hickey FB, Dooley D, O'Brien EC, Moran S, Doherty DG, Little MA., Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non-specific manifestations of renal injury., Clinical & Experimental Immunology, 191, (2), 2018, p180 - 188, Journal Article, PUBLISHED  DOI  URL
Melo, A.M. and Zhang, L. and Dockry, E.F. and Petrasca, A. and Ghnewa, Y.G. and Breen, E.P. and Morrissey, M.E. and O'Reilly, C. and Bruen, R. and O'Meara, A. and Lysaght, J. and Zhu, X. and Doherty, D.G., Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells, Glycobiology, 28, (7), 2018, p512-521 , Notes: [cited By 2], Journal Article, PUBLISHED  DOI
Dunne, P.J. and Maher, C.O. and Freeley, M. and Dunne, K. and Petrasca, A. and Orikiiriza, J. and Dunne, M.R. and Reidy, D. and O'Dea, S. and Loy, A. and Woo, J. and Long, A. and Rogers, T.R. and Mulcahy, F. and Doherty, D.G., CD3ε Expression defines functionally distinct subsets of VÎŽ1 T cells in patients with human immunodeficiency virus infection, Frontiers in Immunology, 9, (MAY), 2018, Notes: [cited By 0], Journal Article, PUBLISHED  TARA - Full Text  DOI
Huggard D, McGrane F, Lagan N, Roche E, Balfe J, Leahy TR, Franklin O, Moreno A, Melo AM, Doherty DG, Molloy EJ, Altered endotoxin responsiveness in healthy children with Down syndrome., BMC immunology, 2018, Journal Article, PUBLISHED  TARA - Full Text  DOI
Doherty, D.G. and Melo, A.M. and Moreno-Olivera, A. and Solomos, A.C., Activation and regulation of B cell responses by invariant natural killer T cells, Frontiers in Immunology, 9, (JUN), 2018, Notes: [cited By 0], Review Article, PUBLISHED  TARA - Full Text  DOI
Arduini S, Dunne J, Conlon N, Feighery C, Doherty D.G, Mucosal-associated invariant T cells are depleted and functionally altered in patients with common variable immunodeficiency, Clinical Immunology, 176, 2017, p23 - 30, Notes: [Export Date: 20 March 2017], Journal Article, PUBLISHED  DOI  URL
  

Page 1 of 11
Core concepts in immunology. in, editor(s)Gershwin ME, Vierling JM, Manns MP , Liver Immunology: Principles and Practice, New York, Springer Science and Business Media, 2014, pp11 - 26, [O'Farrelly C, Doherty DG], Book Chapter, PUBLISHED
Innate immune mechanisms in the liver. in, editor(s)Gershwin ME, Vierling JM, Manns MP , Liver Immunology: Principles and Practices, New Jersey, Humana Press, 2007, pp41-48 , [O'Farrelly C, Doherty DG. ], Notes: [2nd edition], Book Chapter, PUBLISHED
A short primer on fundamental immunology in, editor(s)Gershwin ME, Vierling JM, Manns MP , Liver Immunology: Principles and Practices, New Jersey, Humana Press, 2007, pp15-24 , [O'Farrelly C, Doherty DG. ], Notes: [2nd edition], Book Chapter, PUBLISHED
Lymphocyte repertoires in healthy liver. in, editor(s)Gershwin ME, Vierling JM, Manns MP , Liver Immunology, Philadelphia, Hanley & Belfus, 2003, pp31-46 , [Doherty DG, O'Farrelly C.], Book Chapter, PUBLISHED
Basic immunological terms and concepts: a short primer of fundamental immunology in, editor(s)Gershwin ME, Vierling JM, Manns MP , Liver Immunology, Philadelphia, Hanley & Belfus, 2003, pp1 - 13, [O'Farrelly C, Doherty DG], Book Chapter, PUBLISHED
The human major histocompatibility complex and disease susceptibility. in, Rimoin DL, Connor JM, Pyeritz RE , Emery and Rimoin's Principles and Practice of Medical Genetics, New York, Churchill Livingstone, 1997, pp497-504 , [Doherty DG, Nepom GT. ], Notes: [third edition], Book Chapter, PUBLISHED

  

Award Date
Elected to Fellowship of Trinity College Dublin 2012
Our research is aimed at finding out how the immune system protects against or causes disease in humans and how it can be manipulated for the development of novel therapies. We are particularly interested in populations of 'innate lymphocytes' (natural killer cells, natural killer T cells, gamma/delta T cells and mucosal-associated invariant T cells), which appear to be master regulators of the immune system. Innate lymphocytes can be trained to prevent and treat infectious and immune-mediated diseases and cancers in animal models. Various innate lymphocyte populations are being targeted in clinical trials for cancer in humans, and although the results are promising, no such cellular therapy has yet received approval. In order to improve the efficacy of innate lymphocyte therapies that are currently being tested and to develop new treatments, we are investigating the molecular and cellular interactions that take place between innate lymphocytes, pathogens and other cells. We have shown that innate lymphocytes are heterogeneous with diverse effector functions including tumour cell killing, the release of cytokines that activate or suppress the actions of T cells, and contact-dependent stimulatory and regulatory interactions with monocytes, macrophages, dendritic cells and B cells. In collaboration with clinical colleagues, we have found that innate lymphocyte populations are numerically and/or functionally impaired in patients with hepatitis B and C, HIV, candidiasis, chronic lymphocytic leukaemia, oesophageal, stomach, colorectal, liver and lung cancer, post-operative infection and sepsis, coeliac disease, autoimmune vasculitis, antibody deficiencies and neonatal encephalopathy. Our results show that various innate lymphocyte populations can be manipulated to promote the generation of desirable immune responses for the treatment of multiple diseases and this has led to funded collaborations with three biotechnology/pharmaceutical companies, in which we are pooling our efforts to develop robust therapies for cancer, infectious and autoimmune disease.